by [150+ Pages Report] As per the latest Research and survey report issued by Precedence Research, the global cardiovascular drugs market was valued at around USD 155.6 billion in 2021 and is expected to register revenues worth USD 231.7 billion by the end of 2030, growing at an exceptional CAGR of approximately 4.52% between 2022 and 2030.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/2037
Cardiovascular Drugs Market Report Scope
A recent study by Precedence Research on the cardiovascular drugs market offers a forecast for 2022 and 2030. The study analyzes crucial trends that are currently determining the growth of the cardiovascular drugs market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of cardiovascular drugs. The study also provides the dynamics that are responsible for influencing the future status of the cardiovascular drugs market over the forecast period.
A detailed assessment of the cardiovascular drugs market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the cardiovascular drugs market along with their product portfolio enhances the reliability of this comprehensive research study.
Competition Landscape
The report has engulfed a chapter on the global cardiovascular drugs market’s competitive landscape, which provides detailed analysis and insights on companies offering cardiovascular drugs. Profiles of key companies, along with a strategic overview of their M&A and expansion plans across geographies, have been delivered in this chapter. This chapter is priceless for report readers, as its enables them in gauging their growth potential in the market and implement key strategies for extending their market reach.
This chapter offers key recommendations for both new and existing market participants, enabling them to emerge sustainably and profitably. Intelligence on the market players has been delivered on the basis of their product overview, SWOT analysis, key developments, key financials and company overview. Occupancy of these market participants has been tracked by the report and portrayed via an intensity map.
Read Also@ Cardiovascular Ultrasound Market size is Expected to Surpass Around US$ 2.7 Billion by 2030
Some of the Prominent Players in the Cardiovascular Drugs Market Include:
- Bristol-Myers Squibb Company
- Bayer AG
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Novartis AG
- Merck & Co.
- AstraZeneca
- Sanofi
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche
Cardiovascular Drugs Market Segmentation
By Drug Type
- Antihypertensive
- Anticoagulants
- Antihyperlipidemic
- Antiplatelet Drugs
- Others
By Disease Indication
- Hypertension
- Coronary Artery Disease
- Hyperlipidaemia
- Arrhythmia
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By Drug Classification
- Branded Drugs
- Generic Drugs
By Mode of Purchase
- Prescription-Based Drugs
- Over-The-Counter Drugs
By End Users
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Regional Analysis
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2022 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global cardiovascular drugs market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the cardiovascular drugs market.
The report includes country-wise and region-wise market size for the period 2022-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2022-2030.
Why should you invest in this report?
If you are aiming to enter the global cardiovascular drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cardiovascular drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. End Users Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cardiovascular Drugs Market
5.1. COVID-19 Landscape: Cardiovascular Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cardiovascular Drugs Market, By Drug Type
8.1. Cardiovascular Drugs Market, by Drug Type, 2022-2030
8.1.1. Antihypertensive
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Anticoagulants
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Antihyperlipidemic
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Antiplatelet Drugs
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cardiovascular Drugs Market, By Disease Indication
9.1. Cardiovascular Drugs Market, by Disease Indication, 2022-2030
9.1.1. Hypertension
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Coronary Artery Disease
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hyperlipidaemia
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Arrhythmia
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cardiovascular Drugs Market, By Route of Administration
10.1. Cardiovascular Drugs Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cardiovascular Drugs Market, By Drug Classification
11.1. Cardiovascular Drugs Market, by Drug Classification, 2022-2030
11.1.1. Branded Drugs
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Generic Drugs
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Cardiovascular Drugs Market, By Mode of Purchase
12.1. Cardiovascular Drugs Market, by Mode of Purchase, 2022-2030
12.1.1. Prescription-Based Drugs
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Over-The-Counter Drugs
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Cardiovascular Drugs Market, By End Users
13.1. Cardiovascular Drugs Market, by End Users, 2022-2030
13.1.1. Hospital Pharmacies
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Online Pharmacies
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Retail Pharmacies
13.1.3.1. Market Revenue and Forecast (2017-2030)
13.1.4. Others
13.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Cardiovascular Drugs Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.6. Market Revenue and Forecast, by End Users (2017-2030)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.8.1. Market Revenue and Forecast, by End Users (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.10. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.11. Market Revenue and Forecast, by End Users (2017-2030)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.6. Market Revenue and Forecast, by End Users (2017-2030)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.9. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.10. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.10.1. Market Revenue and Forecast, by End Users (2017-2030)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.12. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.13. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.14. Market Revenue and Forecast, by End Users (2017-2030)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.15.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.15.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.15.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.16. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.16.1. Market Revenue and Forecast, by End Users (2017-2030)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.17.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.17.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.17.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.18. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.18.1. Market Revenue and Forecast, by End Users (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.6. Market Revenue and Forecast, by End Users (2017-2030)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.9. Market Revenue and Forecast, by End Users (2017-2030)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.11. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.11.1. Market Revenue and Forecast, by End Users (2017-2030)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.12.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.12.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.12.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.12.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.12.6. Market Revenue and Forecast, by End Users (2017-2030)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.13.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.13.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.13.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.13.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.13.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.9. Market Revenue and Forecast, by End Users (2017-2030)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.11. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.12. Market Revenue and Forecast, by End Users (2017-2030)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.13.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.13.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.13.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.13.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.13.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.14.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.14.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.14.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.14.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.14.6. Market Revenue and Forecast, by End Users (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.6. Market Revenue and Forecast, by End Users (2017-2030)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.8.1. Market Revenue and Forecast, by End Users (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.9.6. Market Revenue and Forecast, by End Users (2017-2030)
Chapter 15. Company Profiles
15.1. Bristol-Myers Squibb Company
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Bayer AG
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Pfizer Inc
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Janssen Pharmaceuticals, Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Novartis AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Merck & Co.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. AstraZeneca
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Sanofi
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Gilead Sciences, Inc
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. F. Hoffmann-La Roche
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/2037
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
